Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Timothy SpelmanWilliam L HerringCarlos AcostaR HydeVilija G JokubaitisE PucciA LugaresiG LaureysE K HavrdovaD HorakovaG IzquierdoS EichauS OzakbasR AlroughaniT KalincikP DuquetteM GirardT PetersenFrancesco PattiTünde CsépányF GranellaF Grand'MaisonD FerraroR KarabudakM Jose SaM TrojanoV van PeschB Van WijmeerschE CartechiniP McCombeO GerlachD SpitaleriC RozsaS HodgkinsonR BergamaschiR GouiderA SoysalT Castillo-TriviñoJ PrevostJ GarberK de GansR AmpapaM SimoJ L Sanchez-MenoyoG IulianoA SasA van der WaltN JohnO GrayS HughesG De LucaM OnofrjK BuzzardO SkibinaM TerziM SleeC SolaroC Oreja-GuevaraC Ramo-TelloY FragosoV ShaygannejadF MooreC RajdaE Aguera MoralesH ButzkuevenPublished in: Journal of medical economics (2023)
This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.